EMEA-002736-PIP02-23 - paediatric investigation plan

garetosmab
PIPHuman

Key facts

Active Substance
garetosmab
Therapeutic area
Congenital, familial and genetic disorders
Decision number
P/0103/2024
PIP number
EMEA-002736-PIP02-23
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Treatment of fibrodysplasia ossificans progressiva
Route(s) of administration
Intravenous use
Contact for public enquiries

Regeneron Ireland Designated Activity Company 
E-mail: clinicaltrials@regeneron.com  
Tel. +1 9048475385

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Share this page